HLUBF Stock - H. Lundbeck A/S
Unlock GoAI Insights for HLUBF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $22.00B | $19.91B | $18.25B | $16.30B | $17.67B |
| Gross Profit | $17.77B | $15.43B | $14.29B | $12.65B | $13.50B |
| Gross Margin | 80.8% | 77.5% | 78.3% | 77.6% | 76.4% |
| Operating Income | $3.27B | $3.19B | $2.85B | $2.01B | $1.99B |
| Net Income | $3.14B | $2.29B | $1.92B | $1.32B | $1.58B |
| Net Margin | 14.3% | 11.5% | 10.5% | 8.1% | 8.9% |
| EPS | $3.17 | $2.31 | $1.93 | $1.33 | $7.96 |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
Visit WebsiteEarnings History & Surprises
HLUBFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 4, 2026 | — | — | — | — |
Q4 2025 | Nov 11, 2025 | — | $0.17 | — | — |
Q3 2025 | Aug 14, 2025 | — | $0.15 | — | — |
Q2 2025 | May 14, 2025 | — | $0.17 | — | — |
Q1 2025 | Feb 5, 2025 | — | $0.08 | — | — |
Q4 2024 | Nov 13, 2024 | — | $0.12 | — | — |
Q3 2024 | Aug 20, 2024 | — | $0.11 | — | — |
Q2 2024 | May 15, 2024 | — | $0.15 | — | — |
Q1 2024 | Feb 7, 2024 | — | $0.02 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.10 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.09 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.13 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.05 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.09 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.07 | — | — |
Q1 2022 | Mar 31, 2022 | — | $0.06 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.06 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.49 | — | — |
Latest News
Frequently Asked Questions about HLUBF
What is HLUBF's current stock price?
What is the analyst price target for HLUBF?
What sector is H. Lundbeck A/S in?
What is HLUBF's market cap?
Does HLUBF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HLUBF for comparison